BioMarin presents five-year data on Pompe disease treatment

BioMarin presented five-year PROPEL extension data for POMBILITI plus OPFOLDA in late-onset Pompe disease, with ERT-experienced patients showing a 0.7% mean improvement in predicted six-minute walk distance and a 2.8% decline in predicted forced vital capacity. ERT-naive patients showed a 10.5% walk-distance gain at 4.5 years, though forced vital capacity declined 4.4%. Treatment-related adverse events occurred in 51.2% of 82 participants, including five safety-related discontinuations and two serious treatment-related events. The company also reported that its Phase 1/2 Duchenne candidate nivudirsen was generally well tolerated.

Analysis

The primary investable conclusion is data-quality, not clinical read-through: POMBILITI/OPFOLDA is an Amicus Therapeutics (FOLD) franchise, not BioMarin’s. That attribution error, combined with the absence of efficacy detail for BMN 351, means this release should not support any change to BMRN revenue estimates, pipeline probability-of-success, or multiple. Any BMRN move attributable to the Pompe material would be technically driven and likely reversible once investors separate the assets.

For BMRN, BMN 351 is the relevant incremental item, but an early safety characterization without dystrophin, functional, durability, or dose-response data has negligible near-term NPV. The eventual competitive hurdle is high: Sarepta (SRPT) has entrenched exon-51 experience and a large commercial infrastructure, while gene-therapy safety scrutiny raises the bar for all Duchenne programs but could create room for differentiated RNA-based approaches. Over the next 1-3 months, the catalyst is disclosure of biomarker and functional endpoints rather than conference safety language; over 6-18 months, differentiation will depend on whether BMN 351 can show clinically meaningful efficacy with a tolerability profile suitable for chronic pediatric use.

The contrarian angle is that FOLD—not BMRN—could receive modest durability validation from the Pompe extension, but open-label continuation data are vulnerable to survivor bias and lack a contemporaneous comparator. It is insufficient to underwrite material share capture versus Sanofi’s Pompe therapies without evidence on switching, discontinuations, and payer access. This is a watch item rather than a standalone catalyst trade.

Key Decisions for Investors

• No directional BMRN trade on this release. Treat any price reaction linked to the Pompe disclosure as a potential fade only after confirming market attribution; the factual asset mismatch makes the signal non-fundamental.
• Maintain SRPT as the listed competitive benchmark for BMN 351, but do not initiate a BMRN/SRPT pair until BMN 351 reports dystrophin expression and functional outcomes. A credible efficacy signal would favor long BMRN versus short SRPT; safety-only data do not.
• Place an alert on BMRN for BMN 351 dose-escalation efficacy disclosure or regulatory interaction. Reassess upside only if biomarker magnitude, durability, and treatment discontinuation rates indicate differentiation from exon-skipping incumbents; lack of functional evidence by the next substantive update falsifies a near-term pipeline rerating thesis.
• For Pompe exposure, monitor FOLD rather than BMRN. Consider adding only if subsequent disclosures show durable functional stabilization, low discontinuation rates, and evidence of net switching from incumbent ERT; payer friction or worsening safety-related discontinuations would invalidate the thesis.